Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:27 am
Author: Getaka|Social: XLinkedIn

Panacea Biotec Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹81.30Overvalued by 74.98%vs CMP ₹325.00

P/E (15.0) × ROE (4.9%) × BV (₹135.00) × DY (2.00%)

Defaults: P/E=15

₹61.74Overvalued by 81.00%vs CMP ₹325.00
MoS: -426.4% (Negative)Confidence: 58/100 (Moderate)Models: All 5: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹28.8334%Over (-91.1%)
Net Asset ValueAssets₹134.7620%Over (-58.5%)
EV/EBITDAEnterprise₹12.5617%Over (-96.1%)
ROCE CapitalReturns₹62.7914%Over (-80.7%)
Revenue MultipleRevenue₹91.2015%Over (-71.9%)
Consensus (5 models)₹61.74100%Overvalued
Key Drivers: EPS CAGR -64.5% drags value — could be higher if earnings stabilize. | ROE 4.9% is below cost of equity.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -64.5% · Defaults: P/E=15

*Investments are subject to market risks

Investment Snapshot

50
Panacea Biotec Ltd scores 50/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health42/100 · Moderate
ROCE 4.6% WeakROE 4.9% WeakD/E -2.92 Low debtInterest Coverage 0.0x RiskyProfitable 1/5 years Inconsistent
Smart Money60/100 · Moderate
FII holding up 0.20% (6mo) Slight increasePromoter holding at 72.5% Stable
Earnings Quality65/100 · Strong
OPM expanding (-12% → -4%) Improving
Quarterly Momentum60/100 · Moderate
Revenue (4Q): +8% YoY Growing
Industry Rank20/100 · Weak
ROCE 4.6% vs industry 16.4% Below peersROE 4.9% vs industry 15.2% Below peers3Y sales CAGR: -5% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:27 am

Market Cap 1,992 Cr.
Current Price 325
Intrinsic Value₹61.74
High / Low 582/292
Stock P/E
Book Value 135
Dividend Yield0.00 %
ROCE4.57 %
ROE4.92 %
Face Value 1.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Panacea Biotec Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Panacea Biotec Ltd 1,992 Cr. 325 582/292 1350.00 %4.57 %4.92 % 1.00
Hikal Ltd 1,972 Cr. 160 457/14678.9 96.90.88 %9.85 %7.38 % 2.00
Solara Active Pharma Sciences Ltd 2,023 Cr. 459 734/422 3470.00 %6.01 %0.05 % 10.0
Morepen Laboratories Ltd 2,038 Cr. 37.2 70.5/33.026.7 21.80.54 %15.1 %11.8 % 2.00
Unichem Laboratories Ltd 2,100 Cr. 298 712/27820.0 3460.00 %6.24 %5.59 % 2.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Panacea Biotec Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 115.20128.93129.19143.02150.50136.46115.72147.35163.49132.53166.70141.13165.19
Expenses 123.84134.60139.50146.58150.65142.50129.71140.35155.53159.41167.88158.92153.45
Operating Profit -8.64-5.67-10.31-3.56-0.15-6.04-13.997.007.96-26.88-1.18-17.7911.74
OPM % -7.50%-4.40%-7.98%-2.49%-0.10%-4.43%-12.09%4.75%4.87%-20.28%-0.71%-12.61%7.11%
Other Income 41.7134.4433.826.008.4613.556.547.426.3936.3016.999.105.05
Interest 0.961.051.000.910.850.820.870.980.991.040.862.141.85
Depreciation 9.679.519.489.319.118.818.738.688.988.428.398.348.45
Profit before tax 22.4418.2113.03-7.78-1.65-2.12-17.054.764.38-0.046.56-19.176.49
Tax % 13.68%169.63%15.73%6.56%33.33%-6.13%-6.86%1.05%-1.37%4,875.00%39.63%-26.92%40.06%
Net Profit 19.37-12.6810.98-8.29-2.20-1.99-15.884.714.44-1.993.96-14.013.89
EPS in Rs 3.16-2.071.79-1.35-0.37-0.32-2.580.780.74-0.310.66-2.270.65

Last Updated: March 3, 2026, 3:53 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 25, 2026, 7:46 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 510687653544593457544625661460559559606
Expenses 582643541505509591490548674558574584640
Operating Profit -72441123984-1345477-13-98-15-25-34
OPM % -14%6%17%7%14%-29%10%12%-2%-21%-3%-4%-6%
Other Income 1832870628338-1491,687154575567
Interest 1501051271011011051741851814446
Depreciation 71677368575443464439373534
Profit before tax -111-99-19-67-6645-178-1461,449131-8-6
Tax % 2%3%10%-16%15%17%9%1%26%363%201%10%
Net Profit -113-108-21-56-7638-194-1481,078-34-2-9-8
EPS in Rs -18.29-17.38-2.98-8.89-12.076.15-31.69-24.09175.91-5.42-0.19-1.37-1.27
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)4.42%80.56%-166.67%-35.71%150.00%-610.53%23.71%828.38%-103.15%94.12%-350.00%
Change in YoY Net Profit Growth (%)0.00%76.13%-247.22%130.95%185.71%-760.53%634.24%804.67%-931.53%197.27%-444.12%

Panacea Biotec Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-2%
5 Years:1%
3 Years:-5%
TTM:12%
Compounded Profit Growth
10 Years:5%
5 Years:12%
3 Years:21%
TTM:29%
Stock Price CAGR
10 Years:13%
5 Years:19%
3 Years:43%
1 Year:71%
Return on Equity
10 Years:%
5 Years:%
3 Years:-6%
Last Year:-5%

Last Updated: September 5, 2025, 12:05 pm

Balance Sheet

Last Updated: December 4, 2025, 1:46 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 6666666666666
Reserves 507449426350303344193-235871837836829820
Borrowings 1,0601,1111,1059949416467428203420212223
Other Liabilities 371364317440349379449587848407378433405
Total Liabilities 1,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,254
Fixed Assets 1,2761,1441,0711,001949806657609622600582567594
CWIP 17215516130402324341742102128110
Investments 16159775605134033
Other Assets 4796166147506025427035341,114615517592547
Total Assets 1,9431,9301,8541,7891,5981,3761,3901,1781,7591,2711,2411,2901,254

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 543791131118105-30107-108-422-0-27
Cash from Investing Activity + -38-3716-2655-6-35-481,2834301065
Cash from Financing Activity + -30-1-117-107-164-10191-47-1,176-18-3-3
Net Cash Flow -14-1-10-29-22612-2-10735
Free Cash Flow 33085107103100-2189-119-424-71-77
CFO/OP -78%96%64%320%146%-77%-36%141%-2,235%429%-12%108%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-73.0043.00111.00-955.00-857.00-780.00-688.00-743.00-47.00-118.00-36.00-47.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 685279958471464945483747
Inventory Days 375404516770651173344311296292282391
Days Payable 430272318607540572463440327256244413
Cash Conversion Cycle 13184278259195-328-73-8014837625
Working Capital Days -343-12627-46-96-36395-43-229-5-246
ROCE %-8%0%4%2%3%-16%4%5%-6%-10%-4%-5%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 73.59%73.59%73.59%73.59%73.59%73.47%72.87%72.49%72.48%72.48%72.48%72.48%
FIIs 0.18%0.22%0.26%0.26%0.27%0.26%0.37%0.38%1.16%0.79%1.06%1.36%
DIIs 0.43%0.54%0.57%0.69%0.84%1.07%1.16%1.16%1.49%1.52%1.80%1.85%
Public 25.80%25.66%25.58%25.46%25.30%25.21%25.60%25.96%24.86%25.20%24.65%24.31%
No. of Shareholders 48,63447,81548,87847,09146,24245,51339,98235,44633,59334,25633,59334,597

Shareholding Pattern Chart

No. of Shareholders

Panacea Biotec Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF 117 0.02 01172025-04-22 17:25:230%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) -1.37-0.19-5.43175.98-24.11
Diluted EPS (Rs.) -1.37-0.19-5.43175.98-24.11
Cash EPS (Rs.) 4.265.750.87183.11-16.68
Book Value[Excl.RevalReserv]/Share (Rs.) 132.76133.94133.63138.09-41.36
Book Value[Incl.RevalReserv]/Share (Rs.) 132.76133.94133.63138.09-41.36
Revenue From Operations / Share (Rs.) 91.2891.2975.09107.96102.01
PBDIT / Share (Rs.) -0.850.93-7.56-0.4714.14
PBIT / Share (Rs.) -6.54-5.06-13.95-7.606.70
PBT / Share (Rs.) -1.300.242.09236.54-23.56
Net Profit / Share (Rs.) -1.42-0.24-5.51175.98-24.12
NP After MI And SOA / Share (Rs.) -1.37-0.19-5.43175.98-24.11
PBDIT Margin (%) -0.931.02-10.06-0.4313.86
PBIT Margin (%) -7.16-5.53-18.57-7.046.56
PBT Margin (%) -1.420.262.78219.10-23.09
Net Profit Margin (%) -1.55-0.26-7.33163.01-23.64
NP After MI And SOA Margin (%) -1.49-0.20-7.22163.01-23.63
Return on Networth / Equity (%) -1.02-0.14-4.04126.990.00
Return on Capital Employeed (%) -4.34-3.32-9.09-4.755.44
Return On Assets (%) -0.64-0.09-2.6160.47-12.52
Long Term Debt / Equity (X) 0.010.010.010.03-2.92
Total Debt / Equity (X) 0.010.010.010.03-2.92
Asset Turnover Ratio (%) 0.440.440.300.240.31
Current Ratio (X) 1.491.571.711.301.20
Quick Ratio (X) 0.900.991.101.030.79
Inventory Turnover Ratio (X) 2.861.111.021.140.58
Interest Coverage Ratio (X) -1.361.60-10.43-0.010.46
Interest Coverage Ratio (Post Tax) (X) -10.54-9.48-29.74-2.310.21
Enterprise Value (Cr.) 2610.05620.65454.38355.931682.86
EV / Net Operating Revenue (X) 4.671.110.980.532.69
EV / EBITDA (X) -496.96108.22-9.81-122.8619.43
MarketCap / Net Operating Revenue (X) 4.831.331.441.371.74
Price / BV (X) 3.320.900.801.07-4.34
Price / Net Operating Revenue (X) 4.831.331.441.371.74
EarningsYield 0.000.00-0.051.19-0.13

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Panacea Biotec Ltd. is a Public Limited Listed company incorporated on 02/02/1984 and has its registered office in the State of Punjab, India. Company's Corporate Identification Number(CIN) is L33117PB1984PLC022350 and registration number is 022350. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 309.86 Cr. and Equity Capital is Rs. 6.13 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAmbala-Chandigarh Highway, Lalru Punjab 140501Contact not found
Management
NamePosition Held
Dr. Rajesh JainChairman & Managing Director
Mr. Sandeep JainJoint Managing Director
Mr. Ankesh JainWhole Time Director
Mr. Harshet JainWhole Time Director
Mr. Mukul GuptaIndependent Director
Mrs. Ambika SharmaIndependent Director
Dr. Sanjay TrehanDirector - Technical
Mr. Krishan Kumar JalanIndependent Director
Dr. Rajender Pal SinghIndependent Director
Dr. Venkatesh SarvasiddhiIndependent Director
CA. Rajesh Jain.Independent Director

FAQ

What is the intrinsic value of Panacea Biotec Ltd and is it undervalued?

As of 18 April 2026, Panacea Biotec Ltd's intrinsic value is ₹61.74, which is 81.00% lower than the current market price of ₹325.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (4.92 %), book value (₹135), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Panacea Biotec Ltd?

Panacea Biotec Ltd is trading at ₹325.00 as of 18 April 2026, with a FY2026-2027 high of ₹582 and low of ₹292. The stock is currently near its 52-week low. Market cap stands at ₹1,992 Cr..

How does Panacea Biotec Ltd's P/E ratio compare to its industry?

Panacea Biotec Ltd has a P/E ratio of , which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Panacea Biotec Ltd financially healthy?

Key indicators for Panacea Biotec Ltd: ROCE of 4.57 % is on the lower side compared to the industry average of 16.35%; ROE of 4.92 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Panacea Biotec Ltd profitable and how is the profit trend?

Panacea Biotec Ltd reported a net profit of ₹-9 Cr in Mar 2025 on revenue of ₹559 Cr. Compared to ₹1,078 Cr in Mar 2022, the net profit shows a declining trend.

Does Panacea Biotec Ltd pay dividends?

Panacea Biotec Ltd has a dividend yield of 0.00 % at the current price of ₹325.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Panacea Biotec Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports